Estrella Immunopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Estrella Immunopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.80M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($5.54M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.54M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.10M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.10M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.10M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.38M) | Nov 12, 2025 |
| Q1 | 2025 | Sep 30, 2024 | ($3.38M) | Nov 14, 2024 |
| Q2 | 2025 | Jun 30, 2024 | ($3.95M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($3.95M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($469.5K) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($469.5K) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($469.5K) | May 14, 2025 |
| Q3 | 2024 | Dec 31, 2023 | ($1.02M) | May 15, 2024 |
| Q2 | 2023 | Dec 31, 2023 | ($1.02M) | Feb 14, 2024 |
| Q3 | 2024 | Sep 30, 2023 | ($1.87M) | May 15, 2024 |
| Q1 | 2025 | Sep 30, 2023 | ($1.87M) | Nov 14, 2024 |
| Q2 | 2023 | Sep 30, 2023 | ($1.87M) | Feb 14, 2024 |
| Q2 | 2023 | Jun 30, 2023 | ($76.0K) | Aug 1, 2023 |
| Q3 | 2024 | Mar 31, 2023 | ($2.74M) | May 15, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.80M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.54M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.10M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.38M) | Nov 12, 2025 |
| Q1 | 2025 | Sep 30, 2024 | ($3.38M) | Nov 14, 2024 |
| Q2 | 2025 | Jun 30, 2024 | ($3.95M) | Aug 12, 2025 |
| Q3 | 2024 | Mar 31, 2024 | ($469.5K) | May 15, 2024 |
| Q1 | 2025 | Mar 31, 2024 | ($469.5K) | May 14, 2025 |
| Q2 | 2023 | Dec 31, 2023 | ($1.02M) | Feb 14, 2024 |
| Q1 | 2025 | Sep 30, 2023 | ($1.87M) | Nov 14, 2024 |
| Q2 | 2023 | Jun 30, 2023 | ($169.2K) | Aug 1, 2023 |
| Q3 | 2024 | Mar 31, 2023 | ($2.74M) | May 15, 2024 |
| Q2 | 2023 | Dec 31, 2022 | ($2.76M) | Feb 14, 2024 |
| Q3 | 2022 | Sep 30, 2022 | ($549.2K) | Nov 14, 2022 |
| Q1 | 2024 | Sep 30, 2022 | ($2.89M) | Nov 20, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($423.8K) | Aug 1, 2023 |
| Q1 | 2022 | Mar 31, 2022 | ($144.9K) | May 16, 2022 |
| Q3 | 2022 | Sep 30, 2021 | ($108.1K) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($3.6K) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($819) | May 16, 2022 |